<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680341</article-id><article-id pub-id-type="doi">10.3390/v16121930</article-id><article-id pub-id-type="publisher-id">viruses-16-01930</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Vaccination with a Replication-Dead Murine Gammaherpesvirus Lacking Viral Pathogenesis Genes Inhibits WT Virus Infection</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4413-0195</contrib-id><name><surname>Mitra</surname><given-names>Dipanwita</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-viruses-16-01930" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Oldenburg</surname><given-names>Darby G.</given-names></name><xref rid="af2-viruses-16-01930" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Forrest</surname><given-names>J. Craig</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af3-viruses-16-01930" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9648-522X</contrib-id><name><surname>Krug</surname><given-names>Laurie T.</given-names></name><xref rid="af1-viruses-16-01930" ref-type="aff">1</xref><xref rid="c1-viruses-16-01930" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Nicola</surname><given-names>Anthony V.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01930"><label>1</label>HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD 20892, USA; <email>dipa.mitra@nih.gov</email></aff><aff id="af2-viruses-16-01930"><label>2</label>Gundersen Medical Foundation: Virology Research, La Crosse, WI 54601, USA; <email>dgoldenb@gundersenhealth.org</email></aff><aff id="af3-viruses-16-01930"><label>3</label>Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA; <email>jcforrest@uams.edu</email></aff><author-notes><corresp id="c1-viruses-16-01930"><label>*</label>Correspondence: <email>laurie.krug@nih.gov</email>; Tel.: +1-240-858-7042</corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1930</elocation-id><history><date date-type="received"><day>21</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>11</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Gammaherpesviruses are oncogenic pathogens that establish lifelong infections. There are no FDA-approved vaccines against Epstein&#x02013;Barr virus or Kaposi sarcoma herpesvirus. Murine gammaherpesvirus-68 (MHV68) infection of mice provides a system for investigating gammaherpesvirus pathogenesis and testing vaccine strategies. Prime-boost vaccination with a replication-dead virus (RDV) that does not express the essential replication and transactivator protein (RTA) encoded by <italic toggle="yes">ORF50</italic> (RDV-50.stop) protected against WT virus replication and reduced latency in C57BL/6 mice, and prevented lethal disease in <italic toggle="yes">Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mice. To further improve the RDV vaccine and more closely model KSHV vaccine design, we generated an RDV lacking the unique M1-M4 genes and the non-coding tRNA-miRNA-encoded RNAs (TMERs) 6, 7, and 8 that collectively promote latency of MHV68 in vivo. Prime-boost vaccination of mice with RDV-50.stop&#x02206;M1-M4 elicited neutralizing antibodies and virus-specific CD8 T-cell responses in the lungs and spleens, the respective sites of acute replication and latency, that were comparable to RDV-50.stop vaccination. When challenged with WT MHV68, vaccinated mice exhibited a near-complete block of lytic replication and a reduction in latency and reactivation. We conclude that the unique M1-M4 genes and TMERs 6, 7, and 8, which are major determinants of WT MHV68 pathogenesis, are not required for eliciting protective immunity.</p></abstract><kwd-group><kwd>gammaherpesvirus</kwd><kwd>MHV68</kwd><kwd>vaccine</kwd><kwd>replication-dead virus</kwd><kwd>latency establishment</kwd><kwd>reactivation</kwd></kwd-group><funding-group><award-group><funding-source>NIH</funding-source><award-id>R01CA167065</award-id><award-id>R01AI181787</award-id></award-group><funding-statement>This research was supported in part by the Intramural Research Programs of the NIH and the National Cancer Institute (ZIA BC 012014) (L.T.K., D.M.). J.C.F. was supported by NIH grants R01CA167065 and R01AI181787.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01930"><title>1. Introduction</title><p>Kaposi sarcoma herpesvirus (KSHV; human gammaherpesvirus 8) and Epstein&#x02013;Barr virus (EBV; human gammaherpesvirus 4) are cancer-causing gammaherpesviruses (GHVs) that establish chronic persistent infections. KSHV is the causative agent of multiple cancers, including the angioproliferative Kaposi sarcoma (KS) that manifests at cutaneous and visceral sites and two B-cell lymphoproliferative disorders, primary effusion lymphoma, and a variant of multicentric Castleman disease. The seroprevalence of KSHV is &#x0003e;40% in Sub-Saharan Africa (SSA), 10&#x02013;30% in Mediterranean regions, and &#x0003c;10% in northern Europe, Asia, and the USA [<xref rid="B1-viruses-16-01930" ref-type="bibr">1</xref>]. KSHV infection is a significant health burden in people living with HIV (PLWH) worldwide and in endemic areas including SSA [<xref rid="B2-viruses-16-01930" ref-type="bibr">2</xref>]. KSHV associated cancers are a leading cause of morbidity and mortality in PLWH even when HIV is well controlled. Salivary oral transmission occurs in endemic regions, whereas the route of transmission in non-endemic areas, particularly among gay, bisexual, and other men who have sex with men, is less clear [<xref rid="B3-viruses-16-01930" ref-type="bibr">3</xref>]. Blood transfusions and tissue transplants from KSHV-positive donors can also lead to infection [<xref rid="B4-viruses-16-01930" ref-type="bibr">4</xref>,<xref rid="B5-viruses-16-01930" ref-type="bibr">5</xref>]. EBV is ubiquitous and infects more than 90&#x02013;95% of the adult population worldwide. EBV infections can cause infectious mononucleosis (IM), B-cell lymphomas [<xref rid="B6-viruses-16-01930" ref-type="bibr">6</xref>], epithelial-cell cancers [<xref rid="B7-viruses-16-01930" ref-type="bibr">7</xref>], and are etiologically associated with the development of multiple sclerosis [<xref rid="B8-viruses-16-01930" ref-type="bibr">8</xref>,<xref rid="B9-viruses-16-01930" ref-type="bibr">9</xref>]. EBV is primarily transmitted through saliva, but it can also spread via breast milk, other bodily fluids, and transplantation of EBV-positive organs [<xref rid="B6-viruses-16-01930" ref-type="bibr">6</xref>].</p><p>GHV infection in the host comprises lytic replication and periods of quiescent latency. Lytic replication may occur upon initial infection at mucosal sites, followed by a latent program of limited viral gene expression that evades host immune detection [<xref rid="B10-viruses-16-01930" ref-type="bibr">10</xref>,<xref rid="B11-viruses-16-01930" ref-type="bibr">11</xref>]. Reactivation from latency to the lytic phase occurs sporadically and leads to the production of infectious viral progeny, allowing the virus to infect other cellular reservoirs within the host and to spread to new hosts [<xref rid="B11-viruses-16-01930" ref-type="bibr">11</xref>]. Once latency is established, infection is incurable, and individuals are at lifelong risk of cancer from GHV infections [<xref rid="B1-viruses-16-01930" ref-type="bibr">1</xref>]. Immune suppression increases the incidence of GHV cancers and indicates that immune control is key to prevention [<xref rid="B12-viruses-16-01930" ref-type="bibr">12</xref>].</p><p>There is no FDA-approved vaccine against GHVs. Nucleoside analogs reduce lytic infection, but these do not impact the chronic, latent phase infection. A prophylactic ferritin nanoparticle conjugated glycoprotein 350 (gp350) subunit vaccine (NCT04645147) [<xref rid="B13-viruses-16-01930" ref-type="bibr">13</xref>] and an mRNA vaccine containing gp350, gH/gL, and gp42 (NCT05164094) [<xref rid="B14-viruses-16-01930" ref-type="bibr">14</xref>] are in clinical trials for EBV [<xref rid="B15-viruses-16-01930" ref-type="bibr">15</xref>]. There is no KSHV vaccine in clinical trials. An effective vaccine strategy is needed to prevent infection and virus-associated cancers in populations most at risk for disease. One of the major challenges for KSHV vaccine design is the lack of knowledge regarding the immune correlates of protection [<xref rid="B16-viruses-16-01930" ref-type="bibr">16</xref>]. KSHV-specific T-cell responses are weaker compared to EBV in infected individuals [<xref rid="B17-viruses-16-01930" ref-type="bibr">17</xref>]. Additionally, there is a paucity of animal models available to investigate these systems in vivo. Efforts are underway to address this gap in the field, including the recent development of a humanized mouse model of KSHV/EBV co-infection [<xref rid="B18-viruses-16-01930" ref-type="bibr">18</xref>], but this model does not recapitulate all aspects of an antigen-driven immune response and does not support virus infection of non-lymphoid cells.</p><p>Murine gammaherpesvirus 68 (MHV68; murid herpesvirus 4) infection of mice is a model pathogen system with direct genetic and biological correlates to KSHV that is applied to study GHV pathogenesis and define immune correlates of protection [<xref rid="B10-viruses-16-01930" ref-type="bibr">10</xref>,<xref rid="B19-viruses-16-01930" ref-type="bibr">19</xref>]. For both KSHV and MHV68, lytic replication and reactivation is controlled by the replication and transcription activator protein, RTA, encoded by open reading frame 50 (<italic toggle="yes">ORF50</italic>) [<xref rid="B20-viruses-16-01930" ref-type="bibr">20</xref>,<xref rid="B21-viruses-16-01930" ref-type="bibr">21</xref>]. The insertion of a premature translation stop codon in <italic toggle="yes">ORF50</italic> results in a replication-dead virus that infects cells but is unable to replicate [<xref rid="B21-viruses-16-01930" ref-type="bibr">21</xref>]. Previously, we produced a high-titer, revertant-free stock of this virus (RDV-50.stop) in an <italic toggle="yes">ORF50</italic> codon-shuffled producer cell line [<xref rid="B22-viruses-16-01930" ref-type="bibr">22</xref>]. Inoculation with RDV-50.stop exposes the host to intact virion particles and enables limited viral gene expression upon de novo infection, without the production of infectious particles [<xref rid="B23-viruses-16-01930" ref-type="bibr">23</xref>]. We demonstrated that prime-boost intraperitoneal (IP) vaccination of C57BL/6 mice with RDV-50.stop elicited neutralizing antibodies and virus-specific effector T-cell responses in the lungs and spleen, the respective sites of acute replication and latency. When challenged intranasally with WT MHV68, mice vaccinated with RDV-50.stop exhibited a near-complete block in lytic viral replication in the lungs at 7 days (d7) post challenge, and a significant reduction in latency establishment and reactivation from latency in the spleen at d16 post challenge. RDV-50.stop vaccination also protected immunodeficient <italic toggle="yes">Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mice from lethal disease upon WT MHV68 challenge [<xref rid="B23-viruses-16-01930" ref-type="bibr">23</xref>].</p><p>To more closely model KSHV vaccine design and further attenuate the MHV68 RDV-50.stop vaccine platform, the removal of genes unique to MHV68 genes should be considered. A previous study characterized a spontaneous 9.5 kb-deletion mutant of MHV68 (GHV68&#x00394;9473) lacking the M1, M2, M3, and M4 genes in addition to eight small hybrid non-coding RNAs that encode tRNA-like elements linked to miRNAs, termed TMERs [<xref rid="B24-viruses-16-01930" ref-type="bibr">24</xref>]. This spontaneous mutant exhibits a reduction in latency establishment and reactivation from latency in splenocytes [<xref rid="B24-viruses-16-01930" ref-type="bibr">24</xref>]. Results from these studies corroborate with another murine gammaherpesvirus isolate, MHV76, with a slightly larger 9538 bp deletion that encompasses M1-M4 and the eight TMERs [<xref rid="B25-viruses-16-01930" ref-type="bibr">25</xref>]. Upon intranasal infection of mice, MHV76 exhibited a defect in acute replication and increased infiltration of inflammatory cells in the lungs, as well as decreased splenomegaly and establishment of splenic latency. Despite this defect in the early phases of infection, MHV76 established long-term latency in both the lungs and spleen [<xref rid="B25-viruses-16-01930" ref-type="bibr">25</xref>].</p><p>The left-end coding and non-coding genes of MHV68 broadly promote pathogenesis in vivo. MHV68 M1 encodes a superantigen-like factor that stimulates V&#x003b2;4+ CD8 T cells to suppress virus reactivation via IFN&#x003b3; production [<xref rid="B26-viruses-16-01930" ref-type="bibr">26</xref>]. M2 encodes an adapter protein that facilitates latency establishment and reactivation from latency in B cells [<xref rid="B27-viruses-16-01930" ref-type="bibr">27</xref>,<xref rid="B28-viruses-16-01930" ref-type="bibr">28</xref>], augments B-cell survival and proliferation [<xref rid="B27-viruses-16-01930" ref-type="bibr">27</xref>], and promotes MHV68 dissemination to distal latency reservoirs [<xref rid="B29-viruses-16-01930" ref-type="bibr">29</xref>]. M2 is a target for CD4 and CD8 T cells with cytotoxic functions during latency [<xref rid="B30-viruses-16-01930" ref-type="bibr">30</xref>,<xref rid="B31-viruses-16-01930" ref-type="bibr">31</xref>]. M3 encodes for a chemokine-binding protein that inhibits antiviral and inflammatory responses during the acute and latent phases of infection [<xref rid="B32-viruses-16-01930" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01930" ref-type="bibr">33</xref>,<xref rid="B34-viruses-16-01930" ref-type="bibr">34</xref>,<xref rid="B35-viruses-16-01930" ref-type="bibr">35</xref>]. M4 encodes a secreted glycoprotein that promotes splenic latency establishment [<xref rid="B36-viruses-16-01930" ref-type="bibr">36</xref>]. The TMERs broadly promote B-cell latency in immunocompetent mice [<xref rid="B37-viruses-16-01930" ref-type="bibr">37</xref>,<xref rid="B38-viruses-16-01930" ref-type="bibr">38</xref>] and virulence in immunocompromised mice [<xref rid="B39-viruses-16-01930" ref-type="bibr">39</xref>].</p><p>Given that the genetic elements in the M1-M4 locus play critical pathogenic roles in immune modulation, latency and reactivation, we sought to test if loss of these genes would impact the protective immune response generated by an RDV vaccine candidate. Toward this end, we generated a second generation RDV candidate that lacks nucleotides 2022 to 9739 to remove M1, M2, M3, and M4 and TMERs 6, 7, and 8. Here, we test the efficacy of this second-generation RDV vaccine to generate an immune response and protect against WT MHV68 infection in mice.</p></sec><sec id="sec2-viruses-16-01930"><title>2. Materials and Methods</title><sec id="sec2dot1-viruses-16-01930"><title>2.1. Cells and Viruses</title><p>NIH 3T12 mouse fibroblast cells (ATCC CCL-164) and primary murine embryonic fibroblasts (MEFs) prepared from C57BL/6 mice were cultured in Dulbecco&#x02019;s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 IU/mL penicillin, 100 ug/mL streptomycin, and 2 mM L-glutamine, referred to as complete DMEM (cDMEM). Cells were maintained at 37 &#x000b0;C in 5% CO<sub>2</sub>. Reactivation assays were conducted using primary MEFs at passages 3 and 4.</p><p>Viruses utilized in this study include WT MHV68 (WUMS strain) for vaccine challenge experiments and bacterial artificial chromosome (BAC)-derived [<xref rid="B40-viruses-16-01930" ref-type="bibr">40</xref>] replication-deficient RDV-50.stop and RDV-50.stop&#x02206;M1-M4 recombinant MHV68 whose recombineering are described below. WT MHV68 was produced and titered on NIH 3T12 cells. RDV-50.stop and RDV-50.stop&#x02206;M1-M4 recombinant MHV68 were produced and titered on codon-shuffled RTA (CS-RTA)-expressing NIH 3T12 cells [<xref rid="B22-viruses-16-01930" ref-type="bibr">22</xref>], and were validated by plaque assay on vector control cell lines to demonstrate the absence of WT revertants.</p></sec><sec id="sec2dot2-viruses-16-01930"><title>2.2. Generation of Recombinant Viruses</title><p>Oligonucleotide sequences used for recombineering and sequencing are described in <xref rid="app1-viruses-16-01930" ref-type="app">Table S1</xref>. To mutate the ORF50 locus of MHV68, two gBLOCKs (IDT DNA, Coralville, IA, USA) were designed such that there was 30 bp overlap on the 5&#x02032; end of the first gBLOCK (50_STOP_FS_gBLK_1) and the 3&#x02032; end of the second gBLOCK (50_STOP_FS_gBLK_2).</p><p>Similarly, to delete the M1-M4 region of MHV68, two gBLOCKS, M1_4DEL gBLK_1 and M1_4DEL gBLK_2, were designed with a 30 bp overlap. This overlap was engineered to facilitate Gibson assembly using the HiFi Assembly mix (New England Biolabs, Ipswich, MA, USA). The assembled gBLOCKs were diluted 1:4 and 2 uL were used for a PCR using the following primers to generate the full-length targeting construct: 50_STOP_FS_FOR and 50_STOP_FS_REV for RDV-50.stop; M1-4_DEL_FOR and M1-4_DEL_REV for RDV-50.stop&#x02206;M1-M4.</p><p>The 50_STOP or M1-M4_DEL PCR-amplified targeting construct was gel-purified and electroporated into the <italic toggle="yes">en passant E. coli</italic> strain GS1783 [<xref rid="B41-viruses-16-01930" ref-type="bibr">41</xref>] harboring either WT MHV68 BAC or the ORF50.stop mutant BAC clone, respectively. Kanamycin-resistant colonies were chosen for resolution of the kanamycin-resistance cassette that is facilitated by I-SceI digestion and red recombination. Kanamycin-sensitive clones were analyzed for mutation of the ORF50 locus by PCR and subsequent Sanger sequencing of the PCR product, using the primers: 50_FSS_SEQ_FOR and 50_FSS_SEQ_REV. Kanamycin-sensitive clones were analyzed for loss of the M1-M4 region by PCR using the following primers: M1-4_SEQ_FOR and M1-4_SEQ_REV. Clones yielding a 1318 bp PCR product indicated that the M1-M4 region was successfully deleted. Clone #121 (RDV-50.stop) and clone #466 (RDV-50.stop&#x02206;M1-M4) were subject to full genome sequencing via Illumina-based sequencing (Seq Center, Pittsburgh, PA, USA). The resulting reads were analyzed using the Galaxy server and compared to the wild type MHV68 sequence (Genbank: U97553.2) to confirm that the intended M1-M4 region was deleted and the ORF50 frameshift/stop mutations were present. No other differences in the viral genome sequences were observed, excluding repetitive elements.</p></sec><sec id="sec2dot3-viruses-16-01930"><title>2.3. Animal Studies</title><p>Eight- to ten-week-old female C57BL/6 mice (Charles River Laboratories, Wilmington, MA, USA) were anesthetized using 1&#x02013;4% isoflurane and inoculated intraperitoneally (IP) with 1 &#x000d7; 10<sup>6</sup> PFU of RDV-50.stop or RDV-50.stop&#x02206;M1-M4 virions diluted in 500&#x02009;&#x003bc;L cDMEM. These same mice were boosted with an equivalent dose on d28 post prime. Sham-vaccinated mice were inoculated with cDMEM only, and RDV-vaccinated mice were challenged by intranasal (IN) infection with 1 &#x000d7; 10<sup>3</sup> PFU of WT MHV68 diluted in 20 &#x003bc;L cDMEM on d28 post boost. At the indicated timepoints, blood, lung, and spleen tissues were harvested following humane euthanasia using isoflurane or CO<sub>2</sub>.</p><p>All animal procedures reported in this study were performed by NCI-CCR affiliated staff, approved by the NCI Animal Care and Use Committee, and in accordance with federal regulatory requirements and standards. All components of the intramural NIH ACU program are accredited by AAALAC International. Mice were anesthetized prior to inoculation. Mice were humanely euthanized at the indicated experimental endpoints. The humane endpoint criteria, such as signs of distress including lethargy, dehydration, or a bodyweight reduction of 20%, were not reached.</p></sec><sec id="sec2dot4-viruses-16-01930"><title>2.4. Pathogenesis Assays</title><p>To determine acute replication titers, mice were euthanized with isoflurane or CO<sub>2</sub> on d7 post infection (dpi). Both lungs were removed and stored at &#x02212;80 &#x000b0;C, and subsequently disrupted in 1&#x02009;mL of 10% cDMEM using 1&#x02009;mm zirconia beads in a bead beater (Biospec, Bartlesville, OK, USA). NIH 3T12 cells were seeded at a density of 1.8 &#x000d7; 10<sup>5</sup> cells/mL one day prior to infection. Serial dilutions of lung homogenate were overlaid on the NIH 3T12 cells and plaques were scored as previously described [<xref rid="B23-viruses-16-01930" ref-type="bibr">23</xref>].</p><p>For limiting dilution analysis, spleens were homogenized in a TenBroek tissue disrupter. Red blood cells (RBCs) were lysed by incubating in 8.3&#x02009;g/L ammonium chloride for 5&#x02009;min at room temperature with inversion and then diluted with 25&#x02009;mL cDMEM prior to centrifugation. Cells were filtered through a 70- or 100-micron filter prior to enumeration and downstream analyses. Limiting-dilution (LD)-PCR analyses were performed to quantify the frequencies of latently infected splenocytes as previously described [<xref rid="B23-viruses-16-01930" ref-type="bibr">23</xref>,<xref rid="B42-viruses-16-01930" ref-type="bibr">42</xref>]. Control standards were used to confirm single-copy sensitivity and the absence of false-positive amplicons. Amplicons were visualized upon electrophoresis in 1.5% agarose gels stained with SYBR Safe DNA gel stain (Thermo Fisher Scientific, Waltham, MA, USA).</p></sec><sec id="sec2dot5-viruses-16-01930"><title>2.5. Ex Vivo</title><p>The frequency of ex vivo reactivation was determined by co-culture of 2-fold serial dilutions of latently infected splenocytes with MEF monolayers, as previously described [<xref rid="B23-viruses-16-01930" ref-type="bibr">23</xref>,<xref rid="B43-viruses-16-01930" ref-type="bibr">43</xref>]. Preformed infectious virus was detected by plating mechanically disrupted cells on MEF monolayers in parallel. Cytopathic effect was scored on d14 and d21 after plating on MEFs.</p></sec><sec id="sec2dot6-viruses-16-01930"><title>2.6. Flow Cytometry</title><p>Spleens were processed using a tissue grinder and RBC lysis as described above. Lungs were digested using 150 U/mL Collagenase Type IV (Millipore Sigma, Burlington, MA, USA) and 10 U/mL DNaseI for 2 h at 37 &#x000b0;C with intermittent vortexing, followed by RBC lysis. The 2 &#x000d7; 10<sup>6</sup> single cell suspensions prepared from the lung or spleen were resuspended in 200&#x02009;&#x003bc;L of PBS with 2% fetal bovine serum and blocked with TruStain fcX (BioLegend, San Diego, CA, USA). T-cell subsets were identified with previously described antibody panels [<xref rid="B23-viruses-16-01930" ref-type="bibr">23</xref>], with the exception that a 1:5 dilution of H-2K(b)-p79 (cat# JD02150) or H-2D(b)-p56 (cat# JA02153) MHC-peptide dextramer complexes conjugated to PE or APC (Immundex, Fairfax, VA, USA) were added directly to antibody-stained samples. CD8+ T cells were first gated as singlets, then live per exclusion of Alexa Fluor&#x02122; 700 NHS Ester, followed by gating for CD45+ and lymphocytes based on forward and side scatter parameters, and then as CD8+ TCR&#x003b2;.</p></sec><sec id="sec2dot7-viruses-16-01930"><title>2.7. Peptide Stimulation</title><p>To analyze effector T-cell responses, 1 &#x000d7; 10<sup>6</sup> splenocytes were plated into each of five wells of a 96-well flat-bottom plate, either left untreated or treated with 1 ug/mL of p56 (AGPHNDMEI) and p79 (TSINFVKI) peptides (Genscript, Piscataway, NJ, USA) for 5&#x02009;h at 37 &#x000b0;C in the presence of Brefeldin A (BD Cytofix/Cytoperm, BD Biosciences). The Fc receptors were blocked prior to surface staining with antibodies against CD45, TCR&#x003b2; CD8, and CD44 as previously described [<xref rid="B23-viruses-16-01930" ref-type="bibr">23</xref>], with the exception of CD4 (dilution 1:600; clone GK1.5, BV711; cat# 100447; or dilution 1:200; clone GK1.5; AF488; cat# 100423; BioLegend). After fixation and permeabilization with the BD Cytofix/Cytoperm kit (BD Biosciences), the cells were stained with antibodies to cytokines as previously described [<xref rid="B23-viruses-16-01930" ref-type="bibr">23</xref>]. CD8+ T cells were first gated as lymphocytes based on forward and side scatter parameters, singlets, then live per exclusion of Alexa Fluor&#x02122; 700 NHS Ester, followed by gating for CD8+CD45+, and then CD44<sup>hi</sup>.</p></sec><sec id="sec2dot8-viruses-16-01930"><title>2.8. Neutralization Assay</title><p>Serum was prepared by collecting blood from sham-vaccinated or vaccinated mice, followed by centrifugation at 21,100&#x000d7; <italic toggle="yes">g</italic> for 20 min, after which the separated serum was carefully collected. Neutralization was assessed using a plaque reduction neutralization test (PRNT) as previously described on NIH 3T12 cells [<xref rid="B23-viruses-16-01930" ref-type="bibr">23</xref>]. Percent neutralization was determined by comparing the number of plaques in experimental wells to those in no-serum added control wells. Each data point represented the average of three wells.</p></sec><sec id="sec2dot9-viruses-16-01930"><title>2.9. Statistical Analysis</title><p>All data were analyzed using GraphPad Prism software (Version 10, La Jolla, CA, USA). Frequencies of immune cells were analyzed by one-way ANOVA followed by appropriate post-tests based on the parametric distribution, as indicated. The total number of an immune cell subset per animal was log<sub>10</sub>-transformed prior to ANOVA. Titer data were log<sub>10</sub>-transformed and were analyzed using either an unpaired t-test or one-way ANOVA for multiple groups. The frequencies of viral genome-positive cells and reactivation were derived from the nonlinear regression fit of the data with the regression line intersecting at 63.2%, based on the Poisson distribution. The log<sub>10</sub>-transformed frequencies of genome-positive cells and reactivation were analyzed by unpaired, two-tailed t-tests or one-way ANOVA for multiple groups.</p></sec></sec><sec sec-type="results" id="sec3-viruses-16-01930"><title>3. Results</title><sec id="sec3dot1-viruses-16-01930"><title>3.1. Vaccination with RDV-50.stop&#x02206;M1-M4 Induces Virus-Specific Adaptive Immunity in Mice</title><p>The RDV-50.stop and RDV-50.stop&#x02206;M1-M4 mutants were constructed using a BAC recombineering approach [<xref rid="B40-viruses-16-01930" ref-type="bibr">40</xref>]. Our previous study used an ORF50.stop mutant virus with a translation stop codon at amino acid 116 in the RTA protein [<xref rid="B21-viruses-16-01930" ref-type="bibr">21</xref>,<xref rid="B23-viruses-16-01930" ref-type="bibr">23</xref>]. To facilitate recombineering of additional mutations, we recreated the RDV-50.stop mutant in the MHV68 BAC by introducing a frameshift mutation in ORF50 that leads to a stop codon at amino acid 116 in RTA. Nucleotides 2022 to 9739 were subsequently removed to generate RDV-50.stop&#x02206;M1-M4 (<xref rid="app1-viruses-16-01930" ref-type="app">Supplementary Figure S1a</xref>). The &#x02206;M1-M4 deletion was validated by sequencing and restriction fragment length polymorphism analysis, confirming the expected change upon HindIII digestion (<xref rid="app1-viruses-16-01930" ref-type="app">Supplementary Figure S1a,b</xref>).</p><p>To analyze the virus-specific immune response generated by the administration of RDV-50.stop&#x02206;M1-M4 in comparison to RDV-50.stop, WT C57BL/6 mice were inoculated IP with either RDV-50.stop&#x02206;M1-M4 or RDV-50.stop or sham control at d0 for the prime vaccination and again at d28 for the boost vaccination (<xref rid="viruses-16-01930-f001" ref-type="fig">Figure 1</xref>a). At d28 post boost, CD8+ T-cell responses in the lungs and spleen were evaluated by flow cytometry for activation (CD44<sup>hi</sup>) and virus specificity by binding to MHC-I complexes presenting the p56 immunodominant epitope derived from ORF6, the single-stranded DNA binding protein, or the p79 immunodominant epitope derived from ORF6, the ribonucleotide reductase large subunit [<xref rid="B44-viruses-16-01930" ref-type="bibr">44</xref>]. In comparison to na&#x000ef;ve animals, CD8 T cells specific to MHV68 p56 epitopes were detected at higher levels in the lungs of vaccinated mice (<xref rid="viruses-16-01930-f001" ref-type="fig">Figure 1</xref>b,c). Levels of p56 virus-specific T cells were comparable in mice vaccinated with either RDV-50.stop&#x02206;M1-M4 or RDV-50.stop (<xref rid="viruses-16-01930-f001" ref-type="fig">Figure 1</xref>b,c).</p><p>RDV-50.stop&#x02206;M1-M4 vaccination induced abundant virus-specific CD8 T cells in the spleens that were comparable to RDV-50.stop vaccination (<xref rid="viruses-16-01930-f001" ref-type="fig">Figure 1</xref>d&#x02013;h; <xref rid="app1-viruses-16-01930" ref-type="app">Supplementary Figure S2a&#x02013;d</xref>). Splenic CD8 T cells were further identified as KLRG1<sup>+</sup>CD127<sup>&#x02212;</sup> short-lived effector cells (SLECs) and KLRG1<sup>&#x02212;</sup>CD127<sup>+</sup> memory precursor effector cells (MPECs). Virus-specific SLECs (<xref rid="viruses-16-01930-f001" ref-type="fig">Figure 1</xref>d,f; <xref rid="app1-viruses-16-01930" ref-type="app">Supplementary Figure S2b</xref>) and MPECs (<xref rid="viruses-16-01930-f001" ref-type="fig">Figure 1</xref>d,g; <xref rid="app1-viruses-16-01930" ref-type="app">Supplementary Figure S2c</xref>) were comparable in mice vaccinated with either RDV-50.stop&#x02206;M1-M or RDV-50.stop. Vaccination with RDV-50.stop&#x02206;M1-M4 yielded modest changes in memory MPEC populations. RDV-50.stop elicited more CD62L<sup>&#x02212;</sup> effector memory MPEC and RDV-50.stop&#x02206;M1-M4 elicited more CD62L<sup>+</sup> central memory MPEC (<xref rid="viruses-16-01930-f001" ref-type="fig">Figure 1</xref>d,h; <xref rid="app1-viruses-16-01930" ref-type="app">Supplementary Figure S2d</xref>). For both vaccines, the stimulation of splenic CD8 T cells with a combination of p56 and p79 peptides led to the increased production of antiviral effector cytokines TNF&#x003b1; and IFN&#x003b3; in vaccinated mice compared to na&#x000ef;ve mice (<xref rid="viruses-16-01930-f001" ref-type="fig">Figure 1</xref>i,j).</p><p>The neutralization capacity of serum from vaccinated mice was determined by plaque reduction neutralization assays (PRNT; <xref rid="viruses-16-01930-f001" ref-type="fig">Figure 1</xref>k). PRNT50 titers, the dilution of serum to reach 50% neutralization of plaques, indicated that RDV-50.stop&#x02206;M1-M4 elicited comparable levels of virus-neutralizing antibodies to RDV-50.stop. The percentage of V&#x003b2;4+ CD8 T cells in the pooled spleens of prime-boost-vaccinated mice and WT MHV68-infected mice at d28 post inoculation was analyzed by flow cytometry. V&#x003b2;4+ CD8 T cells were increased upon WT MHV68 infection (<xref rid="app1-viruses-16-01930" ref-type="app">Supplementary Figure S2e</xref>), consistent with M1 expression [<xref rid="B26-viruses-16-01930" ref-type="bibr">26</xref>]. V&#x003b2;4+ CD8 T cells were not induced upon vaccination with either RDV-50.stop&#x02206;M1-M4 that lacks M1 or RDV-50.stop that encodes M1 but does not lead to <italic toggle="yes">M1</italic> transcript expression upon infection in culture [<xref rid="B23-viruses-16-01930" ref-type="bibr">23</xref>]. Taken together, RDV-50.stop&#x02206;M1-M4 vaccination elicited virus-specific CD8 T-cell responses and neutralizing antibodies that were comparable to RDV-50.stop.</p><fig position="anchor" id="viruses-16-01930-f001"><label>Figure 1</label><caption><p>RDV-50.stop&#x02206;M1-M4 MHV68 vaccine induces virus-specific immune responses upon a prime-boost vaccination in C57BL/6 mice. (<bold>a</bold>) Schematic representation of prime-boost strategy to evaluate the immune response of C57BL/6 mice to RDV-50.stop&#x02206;M1-M4 or RDV-50.stop vaccination. Mice were prime-boost-vaccinated IP with 1 &#x000d7; 10<sup>6</sup> PFU RDV-50.stop&#x02206;M1-M4 or RDV-50.stop. Na&#x000ef;ve mice were age-matched, non-vaccinated controls. (<bold>b</bold>) Flow cytometric gating strategy to determine the frequency of CD44<sup>hi</sup> CD8 T cells in the lungs that were reactive with the MHV68 p56 epitope at d28 post boost. (<bold>c</bold>) Total p56-dextramer+ CD8 T cells per lung of individual mice. (<bold>d</bold>) Left column, flow cytometric gating strategy to determine the frequency of CD44<sup>hi</sup> CD8 T cells in the spleens that were reactive with viral p56. Middle column, p56-dextramer+ CD8 T cells were further analyzed for markers of short-lived effector cell (SLEC, KLRG1<sup>+</sup>CD127<sup>&#x02212;</sup>) and memory precursor effector cell (MPEC, KLRG1<sup>&#x02212;</sup>CD127<sup>+</sup>) subsets. Right column, MPECs were further delineated into CD62L<sup>&#x02212;</sup> effector and CD62L<sup>+</sup> central MPECs. (<bold>e</bold>) Total p56-dextramer+ CD8 T cells per spleen of individual mice with the indicated vaccination regimen. The percentage of p56-specific CD8 T cells that were SLECs (<bold>f</bold>), MPECs (<bold>g</bold>), and effector vs. memory MPECs (<bold>h</bold>) were enumerated based on the gating strategy for surface markers in (<bold>d</bold>). (<bold>i</bold>) Flow cytometric gating strategy to determine the intracellular cytokine levels of effector cytokines TNF&#x003b1; and IFN&#x003b3; at 5 h after dual stimulation with p79 and p56 peptides. (<bold>j</bold>) Percentage of CD44<sup>hi</sup> CD8 T cells producing both TNF&#x003b1; and IFN&#x003b3;. (<bold>k</bold>) Virus neutralization in serum of vaccinated mice at d28 post boost determined by a plaque reduction assay. For (<bold>c</bold>,<bold>e</bold>&#x02013;<bold>h</bold>,<bold>j</bold>,<bold>k</bold>), symbols represent individual mice (<italic toggle="yes">n</italic> = 5). Bars and whiskers are mean &#x000b1; SD. *, <italic toggle="yes">p</italic> &#x0003c;0.05; **, <italic toggle="yes">p</italic> &#x0003c; 0.01 in the Sidak&#x02019;s (<bold>c</bold>) or Kruskal&#x02013;Wallis (<bold>e</bold>) multiple comparisons test of the one-way ANOVA and in the two-tailed unpaired t test (<bold>f</bold>&#x02013;<bold>h</bold>) and Mann&#x02013;Whitney test (<bold>j</bold>) between the indicated groups.</p></caption><graphic xlink:href="viruses-16-01930-g001" position="float"/></fig></sec><sec id="sec3dot2-viruses-16-01930"><title>3.2. Vaccination with RDV-50.stop&#x02206;M1-M4 Protects Mice from WT MHV68 Challenge</title><p>To determine the protective immunity generated by RDV-50.stop&#x02206;M1-M4 vaccination in vivo, prime-boost-vaccinated mice were challenged by IN infection with 1000 PFU of WT MHV68 at d28 post boost and compared to na&#x000ef;ve and RDV-50.stop-vaccinated animals (<xref rid="viruses-16-01930-f002" ref-type="fig">Figure 2</xref>a). Plaque assays performed on homogenized lung tissue at d7 post challenge revealed significantly lower viral titers in the lungs of vaccinated animals compared to sham-vaccinated controls (<xref rid="viruses-16-01930-f002" ref-type="fig">Figure 2</xref>b). Lung titers were also analyzed at d7 post WT challenge with a higher 5000 PFU dose. In this case, virus replication in the lungs was detected in two of five RDV-50.stop&#x02206;M1-M4-vaccinated mice and in four of five RDV-50.stop-vaccinated mice upon challenge, but there was a significant ~2.5 log reduction in viral titers upon vaccination with either RDV-50.stop&#x02206;M1-M4 or RDV-50.stop compared to sham-vaccinated controls (<xref rid="app1-viruses-16-01930" ref-type="app">Supplementary Figure S3a</xref>). These data demonstrate that vaccination with RDV-50.stop&#x02206;M1-M4 markedly reduces WT virus replication at the mucosal barrier.</p><p>After acute replication in the lung tissue, MHV68 transits through the draining lymph nodes and disseminates to the spleen via the bloodstream [<xref rid="B10-viruses-16-01930" ref-type="bibr">10</xref>]. An increase in spleen weight, termed splenomegaly, is akin to infectious mononucleosis caused by EBV and coincides with virus colonization of the spleen [<xref rid="B45-viruses-16-01930" ref-type="bibr">45</xref>,<xref rid="B46-viruses-16-01930" ref-type="bibr">46</xref>]. WT challenge of sham-vaccinated animals led to a mean 2.8-fold increase in splenomegaly at d17 post challenge (<xref rid="viruses-16-01930-f002" ref-type="fig">Figure 2</xref>c). Vaccination with either RDV-50.stop&#x02206;M1-M4 or RDV-50.stop alone did not cause an increase in spleen weight. Vaccination with either RDV-50.stop prior to WT challenge prevented infection-induced splenomegaly (<xref rid="viruses-16-01930-f002" ref-type="fig">Figure 2</xref>c). Limiting-dilution PCR analyses were performed to measure the frequency of splenocytes that harbor MHV68 genomes. Low frequencies of viral-genome-positive splenocytes were detected upon RDV-50.stop vaccination alone, but not in mice vaccinated with RDV-50.stop&#x02206;M1-M4 (<xref rid="app1-viruses-16-01930" ref-type="app">Supplementary Figure S3b</xref>). Consistent with the loss of RTA encoded by ORF50, vaccination with RDV-50.stop&#x02206;M1-M4 or RDV-50.stop did not result in reactivation from splenocytes (<xref rid="app1-viruses-16-01930" ref-type="app">Supplementary Figure S3c</xref>). With regard to protection, vaccination prior to WT virus challenge resulted in a significant reduction in latently infected cells from 1 in 1149 splenocytes in sham-vaccinated mice to levels below the limit of detection for either RDV-50.stop vaccine (<xref rid="app1-viruses-16-01930" ref-type="app">Figure S2d</xref>). Consistent with the significant reduction in splenic latency, vaccination with either RDV-50.stop resulted in undetectable reactivation in a limiting-dilution ex vivo evaluation of cytopathic effects on an indicator monolayer (<xref rid="viruses-16-01930-f002" ref-type="fig">Figure 2</xref>e). In contrast, splenocytes from sham-vaccinated mice exhibited a typical ex vivo reactivation frequency of 1 in 6497 splenocytes. These data indicate that RDV-50.stop&#x02206;M1-M4 vaccination is as effective as RDV-50.stop in blocking both latency establishment and the subsequent reactivation from latency at d17 post WT challenge, the peak time of MHV68 splenic colonization in mice.</p></sec><sec id="sec3dot3-viruses-16-01930"><title>3.3. Virus-Specific Immune Responses Following Vaccination with RDV-50.stop&#x02206;M1-M4 Correlate with Protection from WT Challenge</title><p>To identify the correlates of immune protection, we next evaluated virus-specific immune responses following WT challenge of mice vaccinated with RDV-50.stop&#x02206;M1-M4 or RDV-50.stop. At d7 post WT MHV68 challenge, CD8 T-cell responses against the p56 immunodominant epitope were significantly higher in the lungs of vaccinated mice in comparison to sham-vaccinated controls (<xref rid="viruses-16-01930-f003" ref-type="fig">Figure 3</xref>a). Stimulation of splenocytes with p56 and p79 peptides led to increased production of antiviral effector cytokines TNF&#x003b1; and IFN&#x003b3; in both cohorts of RDV-vaccinated mice (<xref rid="viruses-16-01930-f003" ref-type="fig">Figure 3</xref>b) compared to sham-vaccinated mice, demonstrating that antigen-specific cells were present and responsive. Total p56-specific CD8 T cells were slightly elevated in the spleens of vaccinated animals (<xref rid="viruses-16-01930-f003" ref-type="fig">Figure 3</xref>c), and total p79-specific CD8 T cells were significantly higher in either vaccinated group compared to sham-vaccinated controls (<xref rid="viruses-16-01930-f003" ref-type="fig">Figure 3</xref>g). Further immunophenotyping revealed that over 30% of p56-specific (<xref rid="viruses-16-01930-f003" ref-type="fig">Figure 3</xref>d) and 50% of p79-specific (<xref rid="viruses-16-01930-f003" ref-type="fig">Figure 3</xref>h) CD44<sup>hi</sup> CD8 T cells in vaccinated mice were SLECs. As expected, mice vaccinated with either RDV-50.stop had higher levels of SLECs than MPECS compared to sham-vaccinated mice (<xref rid="viruses-16-01930-f003" ref-type="fig">Figure 3</xref>d,e,h,i). CD62L analysis of MPECs identified a similar proportion of effector memory MPEC compared to central memory MPEC in both vaccinated groups compared to sham-vaccinated mice (<xref rid="viruses-16-01930-f003" ref-type="fig">Figure 3</xref>f,j). Taken together, prime-boost vaccination with RDV-50.stop&#x02206;M1-M4 elicited virus-specific CD8 T cells that were comparable to RDV-50.stop vaccination. Thus, virus-specific CD8 T effector responses correlate with strong protection afforded to RDV-50.stop-vaccinated mice against WT MHV68 infection.</p><p>We also evaluated the effect of RDV-50.stop&#x02206;M1-M4 vaccination on virus-specific CD8 T-cell responses to WT virus challenge on d17 post challenge, a timepoint that approximates the typical peak of latency establishment in the spleen after IN infection. The quantity of virus-specific CD8 T cells observed at d17 post challenge in the lungs of sham-vaccinated mice surpassed the levels detected in the RDV-50.stop-vaccinated mice upon challenge (<xref rid="viruses-16-01930-f004" ref-type="fig">Figure 4</xref>a). In the case of the spleen at d17 post challenge, p56-specific CD8 T cells were not more numerous in sham-vaccinated mice compared to RDV-50.stop&#x02206;M1-M4-vaccinated mice but exhibited an increased SLEC and CD62L<sup>&#x02212;</sup> effector MPEC phenotype (<xref rid="viruses-16-01930-f004" ref-type="fig">Figure 4</xref>b,c,e). The p79-specific CD8T cells were more abundant in sham-vaccinated mice with a similar effector cell phenotype compared to vaccinated mice (<xref rid="app1-viruses-16-01930" ref-type="app">Supplementary Figure S4a,b,d</xref>). At d17 post challenge, the virus-specific CD8 T-cell response was stronger in the sham-vaccinated mice compared to both RDV-50.stop&#x02206;M1-M4- and RDV-50.stop-vaccinated mice. We attribute this to the lack of pre-existing immunity in sham-vaccinated mice. These unvaccinated mice fail to control the initial acute replication and colonization of the spleen, and this results in a stronger effector T-cell response at d17 post challenge. In contrast, RDV vaccination elicited a pre-existing CD8 T-cell response in both the lungs and spleen that effectively blocked acute replication in the lungs and impaired splenic colonization, leading to a lower overall response at d17 post challenge.</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-16-01930"><title>4. Discussion</title><p>The mouse gammaherpesvirus model is critical to inform vaccine design for KSHV and EBV and to identify the immune components that mediate protection against GHV in the host. In this study, we further refined the RDV-50.stop vaccine platform with the deletion of major pathogenesis determinants of MHV68 in vivo that includes the M1-M4 genes and non-coding TMERs 6-8. We report that prime-boost vaccination with RDV-50.stop&#x02206;M1-M4 elicits virus-neutralizing antibodies and virus-specific CD8 T-cell responses in the lungs and spleen that were comparable to RDV-50.stop vaccination. Importantly, mice vaccinated with either RDV-50.stop were protected from acute virus replication in the lungs and exhibited a reduction in latency establishment coupled with near-complete abolishment of virus reactivation in the splenocytes. Taken together, several pathogenic determinants unique to MHV68 are dispensable for eliciting a protective immune response.</p><p>At the onset of our study, the net impact of the loss of the M1-M4 latency locus on the host immune response to RDV-50.stop had not been reported. M1 drives V&#x003b2;4+ CD8 T-cell expansion that contributes to the control of reactivation from latency [<xref rid="B26-viruses-16-01930" ref-type="bibr">26</xref>]. V&#x003b2;4+ CD8 T cells were not induced in RDV-50.stop&#x02206;M1-M4-vaccinated mice, as expected. Given that RDV-50.stop&#x02206;M1-M4 vaccination was still effective at protection from WT challenge, we conclude that V&#x003b2;4+ CD8 T cells are not an essential immune component for the protection of C57BL/6 mice against the early phases of MHV68 infection in the lung and splenic tissues. Similarly, loss of M2, a known source of cytotoxic T cell epitopes [<xref rid="B30-viruses-16-01930" ref-type="bibr">30</xref>,<xref rid="B31-viruses-16-01930" ref-type="bibr">31</xref>], did not negatively impact the elicitation of protective responses in vaccinated animals. On the other hand, the M3 gene encodes a chemokine-binding protein that dampens immune responses by inhibiting both antiviral and inflammatory activities during infection [<xref rid="B32-viruses-16-01930" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01930" ref-type="bibr">33</xref>,<xref rid="B34-viruses-16-01930" ref-type="bibr">34</xref>,<xref rid="B35-viruses-16-01930" ref-type="bibr">35</xref>]. Given that inflammation may promote immune recruitment and activation, eliminating the M3 gene in a vaccine candidate could potentially improve immunogenicity. However, we observed no enhanced immune response when vaccinating in the absence of the M1-M4 latency locus. Our results are consistent with findings from another study that reported the removal of M1, M2, M3, M4, and ORF4 had no impact on the protection afforded by vaccination with an MHV68 mutant lacking ORF73, which encodes for the latency associated nuclear antigen [<xref rid="B47-viruses-16-01930" ref-type="bibr">47</xref>].</p><p>In our previous study of RDV-50.stop vaccination [<xref rid="B23-viruses-16-01930" ref-type="bibr">23</xref>], we observed low frequencies of splenocytes harboring the RDV-50.stop genome, indicating that it could establish a persistent infection even though reactivation was not possible. This is not an ideal endpoint for a GHV vaccine that expresses viral genes with oncogenic potential. The M2 and M4 genes each contribute to the establishment of latency in the B-cell reservoir by MHV68, leading to the hypothesis that their absence would further attenuate latency. Here, mice vaccinated with RDV-50.stop&#x02206;M1-M4 had qualitatively lower levels of genome-positive cells compared to those vaccinated with RDV-50.stop, albeit the frequency of splenocytes that harbor either vaccine-derived genome were reduced to levels below the limit of absolute quantitation.</p><p>We previously reported that RDV-50.stop-vaccinated mice were protected from WT virus replication in the lungs [<xref rid="B23-viruses-16-01930" ref-type="bibr">23</xref>]. In this study, we demonstrated that both RDV-50.stop&#x02206;M1-M4 and RDV-50.stop protect against acute replication upon IN challenged with 1000 PFU WT MHV68. However, when vaccinated mice were challenged with an increased dose of 5000 PFU, there was a higher breakthrough in acute replication in the lungs. This dose-dependent incidence of breakthrough infection indicates that mucosal immune defenses might be further improved via additional adjuvanted boosts.</p><p>Other animal GHVs reveal the challenges of vaccination strategies to protect livestock and primates. Bovine herpesvirus 4 (BoHV-4) is associated with transplacental infections and reproductive issues in cattle [<xref rid="B48-viruses-16-01930" ref-type="bibr">48</xref>,<xref rid="B49-viruses-16-01930" ref-type="bibr">49</xref>,<xref rid="B50-viruses-16-01930" ref-type="bibr">50</xref>]. Monoclonal antibodies against two BoHV-4 glycoproteins were weakly neutralizing, consistent with poor exposure of these glycoproteins to the immune system of the infected host [<xref rid="B50-viruses-16-01930" ref-type="bibr">50</xref>,<xref rid="B51-viruses-16-01930" ref-type="bibr">51</xref>]. Herpesvirus saimiri (HVS) [<xref rid="B52-viruses-16-01930" ref-type="bibr">52</xref>] is a natural pathogen of squirrel monkeys that causes lethal disease in infected owl monkeys. HVS strategies have included vaccination with inactivated particles, temperature-sensitive mutants, or strains attenuated by serial passaging in culture [<xref rid="B53-viruses-16-01930" ref-type="bibr">53</xref>,<xref rid="B54-viruses-16-01930" ref-type="bibr">54</xref>]. These approaches highlighted the limitations of neutralizing antibodies and the utility of tumorigenesis as an endpoint [<xref rid="B53-viruses-16-01930" ref-type="bibr">53</xref>,<xref rid="B54-viruses-16-01930" ref-type="bibr">54</xref>]. The MHV68 RDV-50.stop vaccine platform offers a distinct advantage by eliciting virus-specific CD8 T-cell responses, providing protective T-cell immunity in addition to neutralizing antibodies. Future studies will examine the impact of removing additional latency determinants on vaccine efficacy and durability.</p></sec><sec sec-type="conclusions" id="sec5-viruses-16-01930"><title>5. Conclusions</title><p>The deletion of unique M1-M4 genes and TMERs 6, 7, and 8 that collectively support WT MHV68 latency and pathogenesis in vivo did not impair the ability of the RDV-50.stop vaccine to elicit protective immunity. These elements were dispensable for generating virus-specific CD8 T cells, neutralizing antibodies, and controlling the replication and reactivation of the WT challenge virus. We conclude that RDV-50.stop&#x02206;M1-M4 is appropriate to further develop as a safe and effective vaccine platform in the mouse GHV pathogen system.</p></sec><sec id="sec6-viruses-16-01930"><title>6. Patents</title><p>JCF and LTK hold a patent [US Patent 11,149,255] for the design and production of the codon-shuffled RTA (CS-RTA)-expressing producer cells to prevent WT revertants of mutants. LTK is divested from potential earnings.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank members of the Krug laboratory for the valuable feedback and insightful discussions.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-viruses-16-01930"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/v16121930/s1">https://www.mdpi.com/article/10.3390/v16121930/s1</uri>, Table S1: Primers, gBLOCKs, and antibodies used in this study. Figure S1: Generation of recombinant RDV-50.stop&#x02206;M1-M4 MHV68 upon deletion of unique M gene locus.; Figure S2: RDV-50.stop&#x02206;M1-M4 generates virus-specific immune responses upon a prime-boost regimen in C57BL/6 mice.; Figure S3: Vaccination with RDV-50.stop&#x02206;M1-M4 reduces acute replication, latency, and reactivation in C57BL/6 mice.; Figure S4: Evaluation of T-cell response to MHV68 in the spleens of vaccinated mice at seventeen days post challenge with WT virus.</p><supplementary-material id="viruses-16-01930-s001" position="float" content-type="local-data"><media xlink:href="viruses-16-01930-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, J.C.F. and L.T.K.; methodology, D.M., D.G.O. and L.T.K.; validation, D.M. and D.G.O.; formal analysis, D.M.; investigation, D.M., D.G.O. and L.T.K.; resources, D.G.O., J.C.F., and L.T.K.; data curation, D.M.; writing&#x02014;original draft preparation, D.M., D.G.O. and L.T.K.; writing&#x02014;review and editing, D.M., D.G.O., J.C.F. and L.T.K.; visualization, D.M., D.G.O., and L.T.K.; supervision, L.T.K.; project administration, J.C.F. and L.T.K.; funding acquisition, J.C.F. and L.T.K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted according to the guidelines of the NCI Animal Care and Use Committee and the National Institutes of Health and approved by the Animal care and Use Committee on 10/03/2022.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data is contained within the article or <xref rid="app1-viruses-16-01930" ref-type="app">Supplementary Materials</xref>.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01930"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cesarman</surname><given-names>E.</given-names></name>
<name><surname>Damania</surname><given-names>B.</given-names></name>
<name><surname>Krown</surname><given-names>S.E.</given-names></name>
<name><surname>Martin</surname><given-names>J.</given-names></name>
<name><surname>Bower</surname><given-names>M.</given-names></name>
<name><surname>Whitby</surname><given-names>D.</given-names></name>
</person-group><article-title>Kaposi sarcoma</article-title><source>Nat. Rev. Dis. Primers</source><year>2019</year><volume>5</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1038/s41572-019-0060-9</pub-id><pub-id pub-id-type="pmid">30705286</pub-id>
</element-citation></ref><ref id="B2-viruses-16-01930"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Casper</surname><given-names>C.</given-names></name>
<name><surname>Corey</surname><given-names>L.</given-names></name>
<name><surname>Cohen</surname><given-names>J.I.</given-names></name>
<name><surname>Damania</surname><given-names>B.</given-names></name>
<name><surname>Gershon</surname><given-names>A.A.</given-names></name>
<name><surname>Kaslow</surname><given-names>D.C.</given-names></name>
<name><surname>Krug</surname><given-names>L.T.</given-names></name>
<name><surname>Martin</surname><given-names>J.</given-names></name>
<name><surname>Mbulaiteye</surname><given-names>S.M.</given-names></name>
<name><surname>Mocarski</surname><given-names>E.S.</given-names></name>
<etal/>
</person-group><article-title>KSHV (HHV8) vaccine: Promises and potential pitfalls for a new anti-cancer vaccine</article-title><source>npj Vaccines</source><year>2022</year><volume>7</volume><fpage>108</fpage><pub-id pub-id-type="doi">10.1038/s41541-022-00535-4</pub-id><pub-id pub-id-type="pmid">36127367</pub-id>
</element-citation></ref><ref id="B3-viruses-16-01930"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Minhas</surname><given-names>V.</given-names></name>
<name><surname>Wood</surname><given-names>C.</given-names></name>
</person-group><article-title>Epidemiology and transmission of Kaposi&#x02019;s sarcoma-associated herpesvirus</article-title><source>Viruses</source><year>2014</year><volume>6</volume><fpage>4178</fpage><lpage>4194</lpage><pub-id pub-id-type="doi">10.3390/v6114178</pub-id><pub-id pub-id-type="pmid">25375883</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01930"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zavitsanou</surname><given-names>A.</given-names></name>
<name><surname>Sypsa</surname><given-names>V.</given-names></name>
<name><surname>Petrodaskalaki</surname><given-names>M.</given-names></name>
<name><surname>Psichogiou</surname><given-names>M.</given-names></name>
<name><surname>Katsoulidou</surname><given-names>A.</given-names></name>
<name><surname>Boletis</surname><given-names>J.</given-names></name>
<name><surname>Hadjiconstantinou</surname><given-names>V.</given-names></name>
<name><surname>Karalis</surname><given-names>D.</given-names></name>
<name><surname>Kalapothaki</surname><given-names>V.</given-names></name>
<name><surname>Hatzakis</surname><given-names>A.</given-names></name>
</person-group><article-title>Human herpesvirus 8 infection in hemodialysis patients</article-title><source>Am. J. Kidney Dis.</source><year>2006</year><volume>47</volume><fpage>167</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2005.09.019</pub-id><pub-id pub-id-type="pmid">16377398</pub-id>
</element-citation></ref><ref id="B5-viruses-16-01930"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Whitby</surname><given-names>D.</given-names></name>
<name><surname>Howard</surname><given-names>M.R.</given-names></name>
<name><surname>Tenant-Flowers</surname><given-names>M.</given-names></name>
<name><surname>Brink</surname><given-names>N.S.</given-names></name>
<name><surname>Copas</surname><given-names>A.</given-names></name>
<name><surname>Boshoff</surname><given-names>C.</given-names></name>
<name><surname>Hatzioannou</surname><given-names>T.</given-names></name>
<name><surname>Suggett</surname><given-names>F.E.</given-names></name>
<name><surname>Aldam</surname><given-names>D.M.</given-names></name>
<name><surname>Denton</surname><given-names>A.S.</given-names></name>
<etal/>
</person-group><article-title>Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi&#x02019;s sarcoma</article-title><source>Lancet</source><year>1995</year><volume>346</volume><fpage>799</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(95)91619-9</pub-id><pub-id pub-id-type="pmid">7674745</pub-id>
</element-citation></ref><ref id="B6-viruses-16-01930"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Damania</surname><given-names>B.</given-names></name>
<name><surname>Kenney</surname><given-names>S.C.</given-names></name>
<name><surname>Raab-Traub</surname><given-names>N.</given-names></name>
</person-group><article-title>Epstein-Barr virus: Biology and clinical disease</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>3652</fpage><lpage>3670</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.08.026</pub-id><pub-id pub-id-type="pmid">36113467</pub-id>
</element-citation></ref><ref id="B7-viruses-16-01930"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kutok</surname><given-names>J.L.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
</person-group><article-title>Spectrum of Epstein-Barr virus-associated diseases</article-title><source>Annu. Rev. Pathol.</source><year>2006</year><volume>1</volume><fpage>375</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1146/annurev.pathol.1.110304.100209</pub-id><pub-id pub-id-type="pmid">18039120</pub-id>
</element-citation></ref><ref id="B8-viruses-16-01930"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soldan</surname><given-names>S.S.</given-names></name>
<name><surname>Lieberman</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Epstein-Barr virus and multiple sclerosis</article-title><source>Nat. Rev. Microbiol.</source><year>2023</year><volume>21</volume><fpage>51</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00770-5</pub-id><pub-id pub-id-type="pmid">35931816</pub-id>
</element-citation></ref><ref id="B9-viruses-16-01930"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bjornevik</surname><given-names>K.</given-names></name>
<name><surname>Munz</surname><given-names>C.</given-names></name>
<name><surname>Cohen</surname><given-names>J.I.</given-names></name>
<name><surname>Ascherio</surname><given-names>A.</given-names></name>
</person-group><article-title>Epstein-Barr virus as a leading cause of multiple sclerosis: Mechanisms and implications</article-title><source>Nat. Rev. Neurol.</source><year>2023</year><volume>19</volume><fpage>160</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1038/s41582-023-00775-5</pub-id><pub-id pub-id-type="pmid">36759741</pub-id>
</element-citation></ref><ref id="B10-viruses-16-01930"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Tibbetts</surname><given-names>S.A.</given-names></name>
<name><surname>Krug</surname><given-names>L.T.</given-names></name>
</person-group><article-title>Conquering the Host: Determinants of Pathogenesis Learned from Murine Gammaherpesvirus 68</article-title><source>Annu. Rev. Virol.</source><year>2021</year><volume>8</volume><fpage>349</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-011921-082615</pub-id><pub-id pub-id-type="pmid">34586873</pub-id>
</element-citation></ref><ref id="B11-viruses-16-01930"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Speck</surname><given-names>S.H.</given-names></name>
<name><surname>Ganem</surname><given-names>D.</given-names></name>
</person-group><article-title>Viral latency and its regulation: Lessons from the gamma-herpesviruses</article-title><source>Cell Host Microbe</source><year>2010</year><volume>8</volume><fpage>100</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2010.06.014</pub-id><pub-id pub-id-type="pmid">20638646</pub-id>
</element-citation></ref><ref id="B12-viruses-16-01930"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lurain</surname><given-names>K.A.</given-names></name>
<name><surname>Ramaswami</surname><given-names>R.</given-names></name>
<name><surname>Krug</surname><given-names>L.T.</given-names></name>
<name><surname>Whitby</surname><given-names>D.</given-names></name>
<name><surname>Ziegelbauer</surname><given-names>J.M.</given-names></name>
<name><surname>Wang</surname><given-names>H.W.</given-names></name>
<name><surname>Yarchoan</surname><given-names>R.</given-names></name>
</person-group><article-title>HIV-associated cancers and lymphoproliferative disorders caused by Kaposi sarcoma herpesvirus and Epstein-Barr virus</article-title><source>Clin. Microbiol. Rev.</source><year>2024</year><volume>37</volume><elocation-id>e0002223</elocation-id><pub-id pub-id-type="doi">10.1128/cmr.00022-23</pub-id><pub-id pub-id-type="pmid">38899877</pub-id>
</element-citation></ref><ref id="B13-viruses-16-01930"><label>13.</label><element-citation publication-type="gov"><article-title>NCT04645147. Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults with or Without EBV Infection</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT04645147" ext-link-type="uri">https://clinicaltrials.gov/study/NCT04645147</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-12">(accessed on 12 December 2024)</date-in-citation></element-citation></ref><ref id="B14-viruses-16-01930"><label>14.</label><element-citation publication-type="gov"><article-title>NCT05164094. A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT05164094" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05164094</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-12">(accessed on 12 December 2024)</date-in-citation></element-citation></ref><ref id="B15-viruses-16-01930"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maple</surname><given-names>P.A.</given-names></name>
<name><surname>Ascherio</surname><given-names>A.</given-names></name>
<name><surname>Cohen</surname><given-names>J.I.</given-names></name>
<name><surname>Cutter</surname><given-names>G.</given-names></name>
<name><surname>Giovannoni</surname><given-names>G.</given-names></name>
<name><surname>Shannon-Lowe</surname><given-names>C.</given-names></name>
<name><surname>Tanasescu</surname><given-names>R.</given-names></name>
<name><surname>Gran</surname><given-names>B.</given-names></name>
</person-group><article-title>The Potential for EBV Vaccines to Prevent Multiple Sclerosis</article-title><source>Front. Neurol.</source><year>2022</year><volume>13</volume><elocation-id>887794</elocation-id><pub-id pub-id-type="doi">10.3389/fneur.2022.887794</pub-id><pub-id pub-id-type="pmid">35812097</pub-id>
</element-citation></ref><ref id="B16-viruses-16-01930"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roshan</surname><given-names>R.</given-names></name>
<name><surname>Labo</surname><given-names>N.</given-names></name>
<name><surname>Trivett</surname><given-names>M.</given-names></name>
<name><surname>Miley</surname><given-names>W.</given-names></name>
<name><surname>Marshall</surname><given-names>V.</given-names></name>
<name><surname>Coren</surname><given-names>L.</given-names></name>
<name><surname>Cornejo Castro</surname><given-names>E.M.</given-names></name>
<name><surname>Perez</surname><given-names>H.</given-names></name>
<name><surname>Holdridge</surname><given-names>B.</given-names></name>
<name><surname>Davis</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>T-cell responses to KSHV infection: A systematic approach</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>109402</fpage><lpage>109416</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.22683</pub-id><pub-id pub-id-type="pmid">29312617</pub-id>
</element-citation></ref><ref id="B17-viruses-16-01930"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nalwoga</surname><given-names>A.</given-names></name>
<name><surname>Whitby</surname><given-names>D.</given-names></name>
</person-group><article-title>Adaptive immune responses to Kaposi&#x02019;s sarcoma-associated herpesvirus</article-title><source>Curr. Opin. Immunol.</source><year>2022</year><volume>77</volume><fpage>102230</fpage><pub-id pub-id-type="doi">10.1016/j.coi.2022.102230</pub-id><pub-id pub-id-type="pmid">35810680</pub-id>
</element-citation></ref><ref id="B18-viruses-16-01930"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caduff</surname><given-names>N.</given-names></name>
<name><surname>Rieble</surname><given-names>L.</given-names></name>
<name><surname>Boni</surname><given-names>M.</given-names></name>
<name><surname>McHugh</surname><given-names>D.</given-names></name>
<name><surname>Roshan</surname><given-names>R.</given-names></name>
<name><surname>Miley</surname><given-names>W.</given-names></name>
<name><surname>Labo</surname><given-names>N.</given-names></name>
<name><surname>Barman</surname><given-names>S.</given-names></name>
<name><surname>Trivett</surname><given-names>M.</given-names></name>
<name><surname>Bosma</surname><given-names>D.M.T.</given-names></name>
<etal/>
</person-group><article-title>KSHV infection of B cells primes protective T cell responses in humanized mice</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>4841</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-49209-w</pub-id><pub-id pub-id-type="pmid">38844783</pub-id>
</element-citation></ref><ref id="B19-viruses-16-01930"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Virgin</surname><given-names>H.W.t.</given-names></name>
<name><surname>Latreille</surname><given-names>P.</given-names></name>
<name><surname>Wamsley</surname><given-names>P.</given-names></name>
<name><surname>Hallsworth</surname><given-names>K.</given-names></name>
<name><surname>Weck</surname><given-names>K.E.</given-names></name>
<name><surname>Dal Canto</surname><given-names>A.J.</given-names></name>
<name><surname>Speck</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Complete sequence and genomic analysis of murine gammaherpesvirus 68</article-title><source>J. Virol.</source><year>1997</year><volume>71</volume><fpage>5894</fpage><lpage>5904</lpage><pub-id pub-id-type="doi">10.1128/jvi.71.8.5894-5904.1997</pub-id><pub-id pub-id-type="pmid">9223479</pub-id>
</element-citation></ref><ref id="B20-viruses-16-01930"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>T.T.</given-names></name>
<name><surname>Usherwood</surname><given-names>E.J.</given-names></name>
<name><surname>Stewart</surname><given-names>J.P.</given-names></name>
<name><surname>Nash</surname><given-names>A.A.</given-names></name>
<name><surname>Sun</surname><given-names>R.</given-names></name>
</person-group><article-title>Rta of murine gammaherpesvirus 68 reactivates the complete lytic cycle from latency</article-title><source>J. Virol.</source><year>2000</year><volume>74</volume><fpage>3659</fpage><lpage>3667</lpage><pub-id pub-id-type="doi">10.1128/JVI.74.8.3659-3667.2000</pub-id><pub-id pub-id-type="pmid">10729142</pub-id>
</element-citation></ref><ref id="B21-viruses-16-01930"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pavlova</surname><given-names>I.V.</given-names></name>
<name><surname>Virgin</surname><given-names>H.W.</given-names></name>
<name><surname>Speck</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Disruption of gammaherpesvirus 68 gene 50 demonstrates that Rta is essential for virus replication</article-title><source>J. Virol.</source><year>2003</year><volume>77</volume><fpage>5731</fpage><lpage>5739</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.10.5731-5739.2003</pub-id><pub-id pub-id-type="pmid">12719566</pub-id>
</element-citation></ref><ref id="B22-viruses-16-01930"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>G.</given-names></name>
<name><surname>Ward</surname><given-names>C.</given-names></name>
<name><surname>Yeasmin</surname><given-names>R.</given-names></name>
<name><surname>Skiena</surname><given-names>S.</given-names></name>
<name><surname>Krug</surname><given-names>L.T.</given-names></name>
<name><surname>Forrest</surname><given-names>J.C.</given-names></name>
</person-group><article-title>A codon-shuffling method to prevent reversion during production of replication-defective herpesvirus stocks: Implications for herpesvirus vaccines</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>44404</elocation-id><pub-id pub-id-type="doi">10.1038/srep44404</pub-id><pub-id pub-id-type="pmid">28287622</pub-id>
</element-citation></ref><ref id="B23-viruses-16-01930"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bland</surname><given-names>W.A.</given-names></name>
<name><surname>Mitra</surname><given-names>D.</given-names></name>
<name><surname>Owens</surname><given-names>S.</given-names></name>
<name><surname>McEvoy</surname><given-names>K.</given-names></name>
<name><surname>Hogan</surname><given-names>C.H.</given-names></name>
<name><surname>Boccuzzi</surname><given-names>L.</given-names></name>
<name><surname>Kirillov</surname><given-names>V.</given-names></name>
<name><surname>Meyer</surname><given-names>T.J.</given-names></name>
<name><surname>Khairallah</surname><given-names>C.</given-names></name>
<name><surname>Sheridan</surname><given-names>B.S.</given-names></name>
<etal/>
</person-group><article-title>A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment</article-title><source>npj Vaccines</source><year>2024</year><volume>9</volume><fpage>116</fpage><pub-id pub-id-type="doi">10.1038/s41541-024-00908-x</pub-id><pub-id pub-id-type="pmid">38914546</pub-id>
</element-citation></ref><ref id="B24-viruses-16-01930"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clambey</surname><given-names>E.T.</given-names></name>
<name><surname>Virgin</surname><given-names>H.W.t.</given-names></name>
<name><surname>Speck</surname><given-names>S.H.</given-names></name>
</person-group><article-title>Characterization of a spontaneous 9.5-kilobase-deletion mutant of murine gammaherpesvirus 68 reveals tissue-specific genetic requirements for latency</article-title><source>J. Virol.</source><year>2002</year><volume>76</volume><fpage>6532</fpage><lpage>6544</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.13.6532-6544.2002</pub-id><pub-id pub-id-type="pmid">12050366</pub-id>
</element-citation></ref><ref id="B25-viruses-16-01930"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Macrae</surname><given-names>A.I.</given-names></name>
<name><surname>Dutia</surname><given-names>B.M.</given-names></name>
<name><surname>Milligan</surname><given-names>S.</given-names></name>
<name><surname>Brownstein</surname><given-names>D.G.</given-names></name>
<name><surname>Allen</surname><given-names>D.J.</given-names></name>
<name><surname>Mistrikova</surname><given-names>J.</given-names></name>
<name><surname>Davison</surname><given-names>A.J.</given-names></name>
<name><surname>Nash</surname><given-names>A.A.</given-names></name>
<name><surname>Stewart</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Analysis of a novel strain of murine gammaherpesvirus reveals a genomic locus important for acute pathogenesis</article-title><source>J. Virol.</source><year>2001</year><volume>75</volume><fpage>5315</fpage><lpage>5327</lpage><pub-id pub-id-type="doi">10.1128/JVI.75.11.5315-5327.2001</pub-id><pub-id pub-id-type="pmid">11333912</pub-id>
</element-citation></ref><ref id="B26-viruses-16-01930"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Evans</surname><given-names>A.G.</given-names></name>
<name><surname>Moser</surname><given-names>J.M.</given-names></name>
<name><surname>Krug</surname><given-names>L.T.</given-names></name>
<name><surname>Pozharskaya</surname><given-names>V.</given-names></name>
<name><surname>Mora</surname><given-names>A.L.</given-names></name>
<name><surname>Speck</surname><given-names>S.H.</given-names></name>
</person-group><article-title>A gammaherpesvirus-secreted activator of Vbeta4+ CD8+ T cells regulates chronic infection and immunopathology</article-title><source>J. Exp. Med.</source><year>2008</year><volume>205</volume><fpage>669</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1084/jem.20071135</pub-id><pub-id pub-id-type="pmid">18332178</pub-id>
</element-citation></ref><ref id="B27-viruses-16-01930"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Siegel</surname><given-names>A.M.</given-names></name>
<name><surname>Herskowitz</surname><given-names>J.H.</given-names></name>
<name><surname>Speck</surname><given-names>S.H.</given-names></name>
</person-group><article-title>The MHV68 M2 protein drives IL-10 dependent B cell proliferation and differentiation</article-title><source>PLoS Pathog.</source><year>2008</year><volume>4</volume><elocation-id>e1000039</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000039</pub-id><pub-id pub-id-type="pmid">18389062</pub-id>
</element-citation></ref><ref id="B28-viruses-16-01930"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Herskowitz</surname><given-names>J.H.</given-names></name>
<name><surname>Jacoby</surname><given-names>M.A.</given-names></name>
<name><surname>Speck</surname><given-names>S.H.</given-names></name>
</person-group><article-title>The murine gammaherpesvirus 68 M2 gene is required for efficient reactivation from latently infected B cells</article-title><source>J. Virol.</source><year>2005</year><volume>79</volume><fpage>2261</fpage><lpage>2273</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.4.2261-2273.2005</pub-id><pub-id pub-id-type="pmid">15681428</pub-id>
</element-citation></ref><ref id="B29-viruses-16-01930"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Owens</surname><given-names>S.M.</given-names></name>
<name><surname>Oldenburg</surname><given-names>D.G.</given-names></name>
<name><surname>White</surname><given-names>D.W.</given-names></name>
<name><surname>Forrest</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Deletion of Murine Gammaherpesvirus Gene M2 in Activation-Induced Cytidine Deaminase-Expressing B Cells Impairs Host Colonization and Viral Reactivation</article-title><source>J. Virol.</source><year>2020</year><volume>95</volume><fpage>e01933-20</fpage><pub-id pub-id-type="doi">10.1128/JVI.01933-20</pub-id><pub-id pub-id-type="pmid">33028711</pub-id>
</element-citation></ref><ref id="B30-viruses-16-01930"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Husain</surname><given-names>S.M.</given-names></name>
<name><surname>Usherwood</surname><given-names>E.J.</given-names></name>
<name><surname>Dyson</surname><given-names>H.</given-names></name>
<name><surname>Coleclough</surname><given-names>C.</given-names></name>
<name><surname>Coppola</surname><given-names>M.A.</given-names></name>
<name><surname>Woodland</surname><given-names>D.L.</given-names></name>
<name><surname>Blackman</surname><given-names>M.A.</given-names></name>
<name><surname>Stewart</surname><given-names>J.P.</given-names></name>
<name><surname>Sample</surname><given-names>J.T.</given-names></name>
</person-group><article-title>Murine gammaherpesvirus M2 gene is latency-associated and its protein a target for CD8(+) T lymphocytes</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1999</year><volume>96</volume><fpage>7508</fpage><lpage>7513</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.13.7508</pub-id><pub-id pub-id-type="pmid">10377445</pub-id>
</element-citation></ref><ref id="B31-viruses-16-01930"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Freeman</surname><given-names>M.L.</given-names></name>
<name><surname>Burkum</surname><given-names>C.E.</given-names></name>
<name><surname>Cookenham</surname><given-names>T.</given-names></name>
<name><surname>Roberts</surname><given-names>A.D.</given-names></name>
<name><surname>Lanzer</surname><given-names>K.G.</given-names></name>
<name><surname>Huston</surname><given-names>G.E.</given-names></name>
<name><surname>Jensen</surname><given-names>M.K.</given-names></name>
<name><surname>Sidney</surname><given-names>J.</given-names></name>
<name><surname>Peters</surname><given-names>B.</given-names></name>
<name><surname>Kohlmeier</surname><given-names>J.E.</given-names></name>
<etal/>
</person-group><article-title>CD4 T cells specific for a latency-associated gamma-herpesvirus epitope are polyfunctional and cytotoxic</article-title><source>J. Immunol.</source><year>2014</year><volume>193</volume><fpage>5827</fpage><lpage>5834</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1302060</pub-id><pub-id pub-id-type="pmid">25378595</pub-id>
</element-citation></ref><ref id="B32-viruses-16-01930"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parry</surname><given-names>C.M.</given-names></name>
<name><surname>Simas</surname><given-names>J.P.</given-names></name>
<name><surname>Smith</surname><given-names>V.P.</given-names></name>
<name><surname>Stewart</surname><given-names>C.A.</given-names></name>
<name><surname>Minson</surname><given-names>A.C.</given-names></name>
<name><surname>Efstathiou</surname><given-names>S.</given-names></name>
<name><surname>Alcami</surname><given-names>A.</given-names></name>
</person-group><article-title>A broad spectrum secreted chemokine binding protein encoded by a herpesvirus</article-title><source>J. Exp. Med.</source><year>2000</year><volume>191</volume><fpage>573</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1084/jem.191.3.573</pub-id><pub-id pub-id-type="pmid">10662803</pub-id>
</element-citation></ref><ref id="B33-viruses-16-01930"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Berkel</surname><given-names>V.</given-names></name>
<name><surname>Barrett</surname><given-names>J.</given-names></name>
<name><surname>Tiffany</surname><given-names>H.L.</given-names></name>
<name><surname>Fremont</surname><given-names>D.H.</given-names></name>
<name><surname>Murphy</surname><given-names>P.M.</given-names></name>
<name><surname>McFadden</surname><given-names>G.</given-names></name>
<name><surname>Speck</surname><given-names>S.H.</given-names></name>
<name><surname>Virgin</surname><given-names>H.I.</given-names></name>
</person-group><article-title>Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action</article-title><source>J. Virol.</source><year>2000</year><volume>74</volume><fpage>6741</fpage><lpage>6747</lpage><pub-id pub-id-type="doi">10.1128/JVI.74.15.6741-6747.2000</pub-id><pub-id pub-id-type="pmid">10888612</pub-id>
</element-citation></ref><ref id="B34-viruses-16-01930"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matuskova</surname><given-names>R.</given-names></name>
<name><surname>Pancik</surname><given-names>P.</given-names></name>
<name><surname>Stibraniova</surname><given-names>I.</given-names></name>
<name><surname>Belvoncikova</surname><given-names>P.</given-names></name>
<name><surname>Rezuchova</surname><given-names>I.</given-names></name>
<name><surname>Kudelova</surname><given-names>M.</given-names></name>
</person-group><article-title>Soluble M3 proteins of murine gammaherpesviruses 68 and 72 expressed in Escherichia coli: Analysis of chemokine-binding properties</article-title><source>Acta Virol.</source><year>2015</year><volume>59</volume><fpage>360</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.4149/av_2015_04_360</pub-id><pub-id pub-id-type="pmid">26666184</pub-id>
</element-citation></ref><ref id="B35-viruses-16-01930"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sebova</surname><given-names>R.</given-names></name>
<name><surname>Bauerova-Hlinkova</surname><given-names>V.</given-names></name>
<name><surname>Beck</surname><given-names>K.</given-names></name>
<name><surname>Nemcovicova</surname><given-names>I.</given-names></name>
<name><surname>Bauer</surname><given-names>J.</given-names></name>
<name><surname>Kudelova</surname><given-names>M.</given-names></name>
</person-group><article-title>Residue Mutations in Murine Herpesvirus 68 Immunomodulatory Protein M3 Reveal Specific Modulation of Chemokine Binding</article-title><source>Front. Cell. Infect Microbiol.</source><year>2019</year><volume>9</volume><elocation-id>210</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2019.00210</pub-id><pub-id pub-id-type="pmid">31293981</pub-id>
</element-citation></ref><ref id="B36-viruses-16-01930"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Evans</surname><given-names>A.G.</given-names></name>
<name><surname>Moorman</surname><given-names>N.J.</given-names></name>
<name><surname>Willer</surname><given-names>D.O.</given-names></name>
<name><surname>Speck</surname><given-names>S.H.</given-names></name>
</person-group><article-title>The M4 gene of gammaHV68 encodes a secreted glycoprotein and is required for the efficient establishment of splenic latency</article-title><source>Virology</source><year>2006</year><volume>344</volume><fpage>520</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2005.08.020</pub-id><pub-id pub-id-type="pmid">16185740</pub-id>
</element-citation></ref><ref id="B37-viruses-16-01930"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feldman</surname><given-names>E.R.</given-names></name>
<name><surname>Kara</surname><given-names>M.</given-names></name>
<name><surname>Oko</surname><given-names>L.M.</given-names></name>
<name><surname>Grau</surname><given-names>K.R.</given-names></name>
<name><surname>Krueger</surname><given-names>B.J.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Feng</surname><given-names>P.</given-names></name>
<name><surname>van Dyk</surname><given-names>L.F.</given-names></name>
<name><surname>Renne</surname><given-names>R.</given-names></name>
<name><surname>Tibbetts</surname><given-names>S.A.</given-names></name>
</person-group><article-title>A Gammaherpesvirus Noncoding RNA Is Essential for Hematogenous Dissemination and Establishment of Peripheral Latency</article-title><source>mSphere</source><year>2016</year><volume>1</volume><fpage>e00105-15</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00105-15</pub-id><pub-id pub-id-type="pmid">27110595</pub-id>
</element-citation></ref><ref id="B38-viruses-16-01930"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Feldman</surname><given-names>E.R.</given-names></name>
<name><surname>Bullard</surname><given-names>W.L.</given-names></name>
<name><surname>Tibbetts</surname><given-names>S.A.</given-names></name>
</person-group><article-title>A Gammaherpesvirus MicroRNA Targets EWSR1 (Ewing Sarcoma Breakpoint Region 1) In Vivo to Promote Latent Infection of Germinal Center B Cells</article-title><source>mBio</source><year>2019</year><volume>10</volume><fpage>e00996-19</fpage><pub-id pub-id-type="doi">10.1128/mBio.00996-19</pub-id><pub-id pub-id-type="pmid">31363027</pub-id>
</element-citation></ref><ref id="B39-viruses-16-01930"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Diebel</surname><given-names>K.W.</given-names></name>
<name><surname>Oko</surname><given-names>L.M.</given-names></name>
<name><surname>Medina</surname><given-names>E.M.</given-names></name>
<name><surname>Niemeyer</surname><given-names>B.F.</given-names></name>
<name><surname>Warren</surname><given-names>C.J.</given-names></name>
<name><surname>Claypool</surname><given-names>D.J.</given-names></name>
<name><surname>Tibbetts</surname><given-names>S.A.</given-names></name>
<name><surname>Cool</surname><given-names>C.D.</given-names></name>
<name><surname>Clambey</surname><given-names>E.T.</given-names></name>
<name><surname>van Dyk</surname><given-names>L.F.</given-names></name>
</person-group><article-title>Gammaherpesvirus small noncoding RNAs are bifunctional elements that regulate infection and contribute to virulence in vivo</article-title><source>mBio</source><year>2015</year><volume>6</volume><fpage>e01670-14</fpage><pub-id pub-id-type="doi">10.1128/mBio.01670-14</pub-id><pub-id pub-id-type="pmid">25691585</pub-id>
</element-citation></ref><ref id="B40-viruses-16-01930"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adler</surname><given-names>H.</given-names></name>
<name><surname>Messerle</surname><given-names>M.</given-names></name>
<name><surname>Wagner</surname><given-names>M.</given-names></name>
<name><surname>Koszinowski</surname><given-names>U.H.</given-names></name>
</person-group><article-title>Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome</article-title><source>J. Virol.</source><year>2000</year><volume>74</volume><fpage>6964</fpage><lpage>6974</lpage><pub-id pub-id-type="doi">10.1128/JVI.74.15.6964-6974.2000</pub-id><pub-id pub-id-type="pmid">10888635</pub-id>
</element-citation></ref><ref id="B41-viruses-16-01930"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tischer</surname><given-names>B.K.</given-names></name>
<name><surname>Smith</surname><given-names>G.A.</given-names></name>
<name><surname>Osterrieder</surname><given-names>N.</given-names></name>
</person-group><article-title>En passant mutagenesis: A two step markerless red recombination system</article-title><source>Methods Mol. Biol.</source><year>2010</year><volume>634</volume><fpage>421</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1007/978-1-60761-652-8_30</pub-id><pub-id pub-id-type="pmid">20677001</pub-id>
</element-citation></ref><ref id="B42-viruses-16-01930"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weck</surname><given-names>K.E.</given-names></name>
<name><surname>Kim</surname><given-names>S.S.</given-names></name>
<name><surname>Virgin</surname><given-names>H.I.</given-names></name>
<name><surname>Speck</surname><given-names>S.H.</given-names></name>
</person-group><article-title>B cells regulate murine gammaherpesvirus 68 latency</article-title><source>J. Virol.</source><year>1999</year><volume>73</volume><fpage>4651</fpage><lpage>4661</lpage><pub-id pub-id-type="doi">10.1128/JVI.73.6.4651-4661.1999</pub-id><pub-id pub-id-type="pmid">10233924</pub-id>
</element-citation></ref><ref id="B43-viruses-16-01930"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weck</surname><given-names>K.E.</given-names></name>
<name><surname>Barkon</surname><given-names>M.L.</given-names></name>
<name><surname>Yoo</surname><given-names>L.I.</given-names></name>
<name><surname>Speck</surname><given-names>S.H.</given-names></name>
<name><surname>Virgin</surname><given-names>H.I.</given-names></name>
</person-group><article-title>Mature B cells are required for acute splenic infection, but not for establishment of latency, by murine gammaherpesvirus 68</article-title><source>J. Virol.</source><year>1996</year><volume>70</volume><fpage>6775</fpage><lpage>6780</lpage><pub-id pub-id-type="doi">10.1128/jvi.70.10.6775-6780.1996</pub-id><pub-id pub-id-type="pmid">8794315</pub-id>
</element-citation></ref><ref id="B44-viruses-16-01930"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stevenson</surname><given-names>P.G.</given-names></name>
<name><surname>Belz</surname><given-names>G.T.</given-names></name>
<name><surname>Altman</surname><given-names>J.D.</given-names></name>
<name><surname>Doherty</surname><given-names>P.C.</given-names></name>
</person-group><article-title>Changing patterns of dominance in the CD8+ T cell response during acute and persistent murine gamma-herpesvirus infection</article-title><source>Eur. J. Immunol.</source><year>1999</year><volume>29</volume><fpage>1059</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1521-4141(199904)29:04&#x0003c;1059::AID-IMMU1059&#x0003e;3.0.CO;2-L</pub-id><pub-id pub-id-type="pmid">10229071</pub-id>
</element-citation></ref><ref id="B45-viruses-16-01930"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sunil-Chandra</surname><given-names>N.P.</given-names></name>
<name><surname>Efstathiou</surname><given-names>S.</given-names></name>
<name><surname>Arno</surname><given-names>J.</given-names></name>
<name><surname>Nash</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Virological and pathological features of mice infected with murine gamma-herpesvirus 68</article-title><source>J. Gen. Virol.</source><year>1992</year><volume>73</volume><issue-part>Pt 9</issue-part><fpage>2347</fpage><lpage>2356</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-73-9-2347</pub-id><pub-id pub-id-type="pmid">1328491</pub-id>
</element-citation></ref><ref id="B46-viruses-16-01930"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sunil-Chandra</surname><given-names>N.P.</given-names></name>
<name><surname>Efstathiou</surname><given-names>S.</given-names></name>
<name><surname>Nash</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Murine gammaherpesvirus 68 establishes a latent infection in mouse B lymphocytes in vivo</article-title><source>J. Gen. Virol.</source><year>1992</year><volume>73</volume><issue-part>Pt 12</issue-part><fpage>3275</fpage><lpage>3279</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-73-12-3275</pub-id><pub-id pub-id-type="pmid">1469366</pub-id>
</element-citation></ref><ref id="B47-viruses-16-01930"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lawler</surname><given-names>C.</given-names></name>
<name><surname>Simas</surname><given-names>J.P.</given-names></name>
<name><surname>Stevenson</surname><given-names>P.G.</given-names></name>
</person-group><article-title>Vaccine protection against murid herpesvirus-4 is maintained when the priming virus lacks known latency genes</article-title><source>Immunol. Cell Biol.</source><year>2020</year><volume>98</volume><fpage>67</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1111/imcb.12299</pub-id><pub-id pub-id-type="pmid">31630452</pub-id>
</element-citation></ref><ref id="B48-viruses-16-01930"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chastant-Maillard</surname><given-names>S.</given-names></name>
</person-group><article-title>Impact of Bovine Herpesvirus 4 (BoHV-4) on Reproduction</article-title><source>Transbound. Emerg. Dis.</source><year>2015</year><volume>62</volume><fpage>245</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1111/tbed.12155</pub-id><pub-id pub-id-type="pmid">23998345</pub-id>
</element-citation></ref><ref id="B49-viruses-16-01930"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Donofrio</surname><given-names>G.</given-names></name>
<name><surname>Franceschi</surname><given-names>V.</given-names></name>
<name><surname>Capocefalo</surname><given-names>A.</given-names></name>
<name><surname>Cavirani</surname><given-names>S.</given-names></name>
<name><surname>Sheldon</surname><given-names>I.M.</given-names></name>
</person-group><article-title>Isolation and characterization of bovine herpesvirus 4 (BoHV-4) from a cow affected by post partum metritis and cloning of the genome as a bacterial artificial chromosome</article-title><source>Reprod. Biol. Endocrinol.</source><year>2009</year><volume>7</volume><elocation-id>83</elocation-id><pub-id pub-id-type="doi">10.1186/1477-7827-7-83</pub-id><pub-id pub-id-type="pmid">19691825</pub-id>
</element-citation></ref><ref id="B50-viruses-16-01930"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Romeo</surname><given-names>F.</given-names></name>
<name><surname>Spetter</surname><given-names>M.J.</given-names></name>
<name><surname>Pereyra</surname><given-names>S.B.</given-names></name>
<name><surname>Moran</surname><given-names>P.E.</given-names></name>
<name><surname>Gonzalez Altamiranda</surname><given-names>E.A.</given-names></name>
<name><surname>Louge Uriarte</surname><given-names>E.L.</given-names></name>
<name><surname>Odeon</surname><given-names>A.C.</given-names></name>
<name><surname>Perez</surname><given-names>S.E.</given-names></name>
<name><surname>Verna</surname><given-names>A.E.</given-names></name>
</person-group><article-title>Whole Genome Sequence-Based Analysis of Bovine Gammaherpesvirus 4 Isolated from Bovine Abortions</article-title><source>Viruses</source><year>2024</year><volume>16</volume><elocation-id>739</elocation-id><pub-id pub-id-type="doi">10.3390/v16050739</pub-id><pub-id pub-id-type="pmid">38793621</pub-id>
</element-citation></ref><ref id="B51-viruses-16-01930"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dubuisson</surname><given-names>J.</given-names></name>
<name><surname>Guillaume</surname><given-names>J.</given-names></name>
<name><surname>Boulanger</surname><given-names>D.</given-names></name>
<name><surname>Thiry</surname><given-names>E.</given-names></name>
<name><surname>Bublot</surname><given-names>M.</given-names></name>
<name><surname>Pastoret</surname><given-names>P.P.</given-names></name>
</person-group><article-title>Neutralization of bovine herpesvirus type 4 by pairs of monoclonal antibodies raised against two glycoproteins and identification of antigenic determinants involved in neutralization</article-title><source>J. Gen. Virol.</source><year>1990</year><volume>71</volume><issue-part>Pt 3</issue-part><fpage>647</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-71-3-647</pub-id><pub-id pub-id-type="pmid">1690263</pub-id>
</element-citation></ref><ref id="B52-viruses-16-01930"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fickenscher</surname><given-names>H.</given-names></name>
<name><surname>Fleckenstein</surname><given-names>B.</given-names></name>
</person-group><article-title>Herpesvirus saimiri</article-title><source>Philos. Trans. R Soc. Lond. B Biol. Sci.</source><year>2001</year><volume>356</volume><fpage>545</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1098/rstb.2000.0780</pub-id><pub-id pub-id-type="pmid">11313011</pub-id>
</element-citation></ref><ref id="B53-viruses-16-01930"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ablashi</surname><given-names>D.V.</given-names></name>
<name><surname>Easton</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Preventive vaccination against Herpesvirus saimiri-induced neoplasia</article-title><source>Cancer Res.</source><year>1976</year><volume>36</volume><fpage>701</fpage><lpage>703</lpage><pub-id pub-id-type="pmid">175928</pub-id>
</element-citation></ref><ref id="B54-viruses-16-01930"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laufs</surname><given-names>R.</given-names></name>
<name><surname>Steinke</surname><given-names>H.</given-names></name>
</person-group><article-title>Vaccination of nonhuman primates with killed oncogenic herpesviruses</article-title><source>Cancer Res.</source><year>1976</year><volume>36</volume><fpage>704</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">175929</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-16-01930-f002"><label>Figure 2</label><caption><p>Vaccination with RDV-50.stop&#x02206;M1-M4 reduces acute replication, splenomegaly, latency and reactivation of wild-type MHV68 upon challenge in C57BL/6 mice. (<bold>a</bold>) Schematic describing mice either sham-vaccinated or prime-boost-vaccinated IP with 1 &#x000d7; 10<sup>6</sup> PFU of RDV-50.stop&#x02206;M1-M4 or RDV-50.stop followed by IN challenge with 1 &#x000d7; 10<sup>3</sup> PFU of WT MHV68 at d28 post boost. Na&#x000ef;ve mice were age-matched, non-vaccinated controls. (<bold>b</bold>) Acute replication at d7 post challenge determined by measuring infectious particles per ml lung homogenate. (<bold>c</bold>) Splenomegaly determined by spleen weights at d17 post challenge. Symbols denote individual mice (<italic toggle="yes">n</italic> = 5&#x02013;15 mice per experiment); bars and whiskers represent mean &#x000b1; SD. ****, <italic toggle="yes">p</italic> &#x0003c; 0.0001 in Sidak&#x02019;s multiple comparisons test of one-way ANOVA (<bold>b</bold>,<bold>c</bold>) between the indicated groups. (<bold>d</bold>) The frequency of latency determined by limiting dilution nested PCR of intact splenocytes for the viral genome at d17 post challenge. (<bold>e</bold>) The frequency of explant reactivation determined by limiting dilution coculture of intact viable splenocytes on a monolayer of primary MEFs d17 post challenge. Disrupted splenocytes plated in parallel did not detect preformed infectious virus in the vaccinated animals. For (<bold>d</bold>,<bold>e</bold>), symbols denote the average of two experiments with five mice per experiment; error bars represent SEM.</p></caption><graphic xlink:href="viruses-16-01930-g002" position="float"/></fig><fig position="float" id="viruses-16-01930-f003"><label>Figure 3</label><caption><p>Evaluation of T-cell response to MHV68 in the lungs and spleens of vaccinated mice at seven days post challenge with WT virus. C57BL/6 mice were either sham-vaccinated or prime-boost-vaccinated IP with 1 &#x000d7; 10<sup>6</sup> PFU RDV-50.stop&#x02206;M1-M4 or RDV-50.stop followed by IN challenge with 1 &#x000d7; 10<sup>3</sup> PFU WT MHV68 at d28 post boost and analyzed d7 post challenge. (<bold>a</bold>) Total p56-dextramer+ CD8 T cells per lung of individual mice after prime + boost + challenge. (<bold>b</bold>) Intracellular cytokine levels of effector cytokines TNF&#x003b1; and IFN&#x003b3; were examined 6 h after dual stimulation with p56 and p79 peptides. Total (<bold>c</bold>) p56-dextramer+ or (<bold>g</bold>) p79-tetramer+ CD8 T cells per spleen of individual mice. Percentage of p56-tetramer+ or p79-dextramer+ CD8 T cells (<bold>d</bold>,<bold>h</bold>) with markers of SLEC and (<bold>e</bold>,<bold>i</bold>) MPEC subsets (<bold>f</bold>,<bold>j</bold>). MPECs were further delineated into effector and central MPECs for p56-dextramer+ or p79-dextramer+ CD8 T cells. For each graph, symbols represent individual mice, (<italic toggle="yes">n</italic> = 3&#x02013;5); bars and whiskers are mean &#x000b1; SD. **, <italic toggle="yes">p</italic> &#x0003c; 0.01; ***, <italic toggle="yes">p</italic> &#x0003c; 0.001; ****, <italic toggle="yes">p</italic> &#x0003c; 0.0001 in Sidak&#x02019;s multiple comparisons test of one-way ANOVA between the indicated groups.</p></caption><graphic xlink:href="viruses-16-01930-g003" position="float"/></fig><fig position="float" id="viruses-16-01930-f004"><label>Figure 4</label><caption><p>Evaluation of T-cell response to MHV68 in the lungs and spleens of vaccinated mice at seventeen days post challenge with WT virus. C57BL/6 mice were either sham-vaccinated or prime-boost-vaccinated IP with 1 &#x000d7; 10<sup>6</sup> PFU RDV-50.stop&#x02206;M1-M4 or RDV-50.stop followed by challenge with 1 &#x000d7; 10<sup>3</sup> PFU WT MHV68 at d28 post boost and analyzed d17 post challenge. (<bold>a</bold>) Total p56-dextramer+ CD8 T cells per lung of individual mice after prime + boost + challenge. (<bold>b</bold>) Total p56-dextramer+ CD8 T cells per spleen of individual mice. Percentage of p56-dextramer+ CD8 T cells with markers of (<bold>c</bold>) SLEC and (<bold>d</bold>) MPEC subsets. (<bold>e</bold>) MPECs were further delineated into effector and central MPECs for p56-dextramer+ CD8 T cells. For each graph, symbols represent individual mice, (<italic toggle="yes">n</italic> = 2&#x02013;5); bars and whiskers are mean &#x000b1; SD. *, <italic toggle="yes">p</italic> &#x0003c; 0.05; ***, <italic toggle="yes">p</italic> &#x0003c; 0.001; ****, <italic toggle="yes">p</italic> &#x0003c; 0.0001 in Sidak&#x02019;s multiple comparisons test of one-way ANOVA between the indicated groups.</p></caption><graphic xlink:href="viruses-16-01930-g004" position="float"/></fig></floats-group></article>